AR084598A1 - METODO PARA TRATAR LA PIEL CON MODULADORES DE microARN - Google Patents

METODO PARA TRATAR LA PIEL CON MODULADORES DE microARN

Info

Publication number
AR084598A1
AR084598A1 ARP110104940A ARP110104940A AR084598A1 AR 084598 A1 AR084598 A1 AR 084598A1 AR P110104940 A ARP110104940 A AR P110104940A AR P110104940 A ARP110104940 A AR P110104940A AR 084598 A1 AR084598 A1 AR 084598A1
Authority
AR
Argentina
Prior art keywords
mir
nrn
hydrogen
skin
active agent
Prior art date
Application number
ARP110104940A
Other languages
English (en)
Original Assignee
Avon Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avon Prod Inc filed Critical Avon Prod Inc
Publication of AR084598A1 publication Critical patent/AR084598A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/17—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/148—Screening for cosmetic compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Reivindicación 1: Un método para mejorar la apariencia estética de la piel humana que comprende la aplicación tópica en un zona de la piel que lo necesita de una eficiente de un agente activo que suprime a miR-29a, que tiene la secuencia UAGCACCAUCUGAAAUCGGUUA (SEC. ID. Nº 1), y/o a miR-29b, que tiene la secuencia UAGCACCAUUUGAAAUCAGUGUU (SEC. ID Nº 2), en un vehículo cosméticamente aceptable durante el tiempo suficiente para aumentar la producción de colágeno, elastina y/o fibrilina en la piel.Reivindicación 4: El método de acuerdo con la reivindicación 1, donde dicho agente activo suprime a miR-29a y a miR-29b. Reivindicación 5: El método de acuerdo con la reivindicación 4, donde dicho agente activo es un compuesto que tiene la estructura de la fórmula (1), donde: R1 y R2 son independientemente hidrógeno, -R, o -C(=O)R*, donde R1 y R2 junto con el átomo de nitrógeno al cual están unidos pueden formar un anillo de tres a seis miembros; R3 se selecciona de hidrógeno, -R, -OR*, -SR*, y -N(RN)(R*); R4 y R5 se seleccionan independientemente en cada ocurrencia de hidrógeno; -R; o X1; y donde dos grupos adyacentes R5 cualesquiera pueden formar un anillo de cinco o seis miembros que se fusionan al anillo de benceno al cual están unidos; R6 es hidrógeno, -R, o -C(=O)R*; R, R*, y RN son independientemente hidrógeno o un radical de hidrocarburo C1-20; donde dicho radical de hidrocarburo C1-20 puede ser sustituido opcionalmente con un grupo X1 y/o con uno a doce heteroátomos seleccionados de oxígeno, nitrógeno, y azufre; X1 se selecciona del grupo que consta de -F; -Cl; -Br; -I; -OH; -CºC-R*; -CºN; -C(R)=N-RN; -C=N-N(RN)2; -C(=NRN)-N(RN)2; -CH2OH; -CHO; -(C=O)-R*; -CO2H; -CO2-; -CO2R*; -CS2R*; -(C=O)-S-R*; -S-(C=O)-R*; -(C=O)-NH2; -(C=O)-NRNRN; -(C=O)-NHNH2; -O-(C=O)-NHNH2; -(C=S)-NH2; -(C=S)-N(RN)2; -O-(C=O)-H; -O(C=O)-R*; -O-(C=O)-NH2; -O-(C=O)-NRNRN; -OR*; -SR*; -NH2; -NHRN; -NRN2; -N(RN)3+; -N(RN)-OH; -N(®O)(R*)2; -O-N(RN)2; -N(RN)-O-R*; -N(RN)-N(RN)2; -NRN-(C=O)-R*; -NRNC(=O)O-R*; -NRN-CHO; -NRN-(C=O)-R*; -NRNC(=O)NRN; -N(RN)-C(=O)-N(RN)2; -N(RN)-C(=S)-N(RN)2; -N=C(R*)2; -N=N-RN; -SCN; -NCS; -NSO; -SS-R*; -SO-R*; -SO2-R*; -O-S(=O)2-R*; -S(=O)2OR*; -N(RN)-SO2-R*; -SO2-N(R*)2; -O-SO3-; -O-S(=O)2-OR*; -O-S(=O)OR*; -O-S(=O)R*; -S(=O)-OR*; -S(=O)-R*; -NO; -NO2; -NO3; -O-NO; -O-NO2; -N3; -N2; -N(C2H4); -Si(R*)3; -CF3; -O-CF3; -(C=O)-R*; P(R*)2; -O-P(=O)(OR*)2 y -P(=O)(OR*)2; “n” es un entero de 0 a 3, y, en el caso donde “n” es 2 ó 3, R5 se selecciona independientemente en cada ocurrencia; y sales de adición ácida cosméticamente aceptables de los mismos. Reivindicación 19: Un método para identificar agentes activos útiles para mejorar la apariencia estética de la piel que comprende ensayar sustancias candidatas por su capacidad para suprimir o disminuir miR-29a y/o miR-29b en una célula.
ARP110104940A 2010-12-28 2011-12-27 METODO PARA TRATAR LA PIEL CON MODULADORES DE microARN AR084598A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/979,695 US8455518B2 (en) 2010-12-28 2010-12-28 Method of treating skin with microRNA modulators

Publications (1)

Publication Number Publication Date
AR084598A1 true AR084598A1 (es) 2013-05-29

Family

ID=46317882

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110104940A AR084598A1 (es) 2010-12-28 2011-12-27 METODO PARA TRATAR LA PIEL CON MODULADORES DE microARN

Country Status (12)

Country Link
US (2) US8455518B2 (es)
EP (1) EP2658537B1 (es)
JP (1) JP5918783B2 (es)
CN (2) CN104622704B (es)
AR (1) AR084598A1 (es)
BR (1) BR112013014597B1 (es)
CA (2) CA2817395C (es)
HK (2) HK1206591A1 (es)
MX (2) MX345299B (es)
PL (1) PL2658537T3 (es)
TW (1) TWI605833B (es)
WO (1) WO2012091824A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815265B2 (en) * 2010-06-30 2014-08-26 Avon Products, Inc. Cosmetic use of N-substituted sulfonyloxybenzylamines and related compounds
JP5850929B2 (ja) 2010-06-30 2016-02-03 エイボン プロダクツ インコーポレーテッド Ｍａｇｐ−１に刺激を与えて皮膚の外観を改善する組成物
US8632827B2 (en) 2011-12-13 2014-01-21 Avon Products, Inc Modulation of thymosin beta-4 in skin
JP6120398B2 (ja) * 2012-11-02 2017-04-26 国立大学法人三重大学 水溶性フィブリリン組成物による弾性線維増強法
WO2014093053A1 (en) * 2012-12-11 2014-06-19 Avon Products, Inc. Modulation of thymosin beta-4 in skin
US9186316B2 (en) 2012-12-11 2015-11-17 Avon Products, Inc. Stephanotis jasminoides extracts and methods of use
WO2014092686A1 (en) * 2012-12-11 2014-06-19 Avon Products, Inc. Stephanotis jasminoides extracts and methods of use
TW201422246A (zh) 2012-12-11 2014-06-16 Avon Prod Inc 藉由調節ｗｉｐｉ－１改善皮膚老化外觀之方法
US9445981B2 (en) * 2012-12-20 2016-09-20 Avon Products, Inc PLOD-2 stimulators and their use in the treatment of skin
CN110205366B (zh) * 2018-02-28 2022-06-21 伽蓝（集团）股份有限公司 一种皮肤内源性老化靶标的筛选方法及改善皮肤内源性老化的活性物及其筛选方法
CN111041082B (zh) * 2018-10-11 2023-11-07 伽蓝（集团）股份有限公司 一种以皮肤光老化靶标筛选改善皮肤光老化的活性物的方法及改善皮肤光老化的活性物
CN111249466B (zh) * 2020-03-14 2022-04-15 浙江大学医学院附属第一医院 丹参酮ⅡA与miR-29b抑制剂联合在制备治疗肌腱粘连的药物中的应用
WO2023012722A1 (en) * 2021-08-06 2023-02-09 Leadermed Champion Limited miRNA-BASED COMPOSITIONS AND METHODS OF USE THEREOF

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9918023D0 (en) * 1999-07-30 1999-09-29 Unilever Plc Skin care composition
EP2385123B1 (en) 2001-09-28 2018-04-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Microrna molecules
UA82835C2 (en) * 2001-12-03 2008-05-26 Reddys Lab Ltd Dr ?-aryl-?-oxysubstituted propionuc acid derivatives and pharmaceutical composition based thereon
EP2295604B1 (en) 2004-02-09 2015-04-08 Thomas Jefferson University Diagnosis and treatment of cancers with microRNA located in or near cancer-associated chromosomal features
WO2006133588A1 (en) * 2005-06-13 2006-12-21 Oncalis Ag ARYL UREA COMPOUNDS AS β-SECRETASE INHIBITORS
JP5192380B2 (ja) * 2005-09-08 2013-05-08 株式會社アモーレパシフィック 皮膚老化防止用皮膚外用剤組成物
WO2009018492A2 (en) * 2007-07-31 2009-02-05 The Board Of Regents Of The University Of Texas System Micro-rnas that control myosin expression and myofiber identity
JP5587777B2 (ja) * 2007-07-31 2014-09-10 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 線維症をモジュレートするマイクロｒｎａファミリー及びその使用
EP2491007B1 (en) 2009-10-23 2013-09-25 Boehringer Ingelheim International GmbH Inhibitors of the microsomal prostaglandin E2 synthase-1
US8815265B2 (en) * 2010-06-30 2014-08-26 Avon Products, Inc. Cosmetic use of N-substituted sulfonyloxybenzylamines and related compounds
JP5850929B2 (ja) * 2010-06-30 2016-02-03 エイボン プロダクツ インコーポレーテッド Ｍａｇｐ−１に刺激を与えて皮膚の外観を改善する組成物
CA2822328A1 (en) * 2010-12-30 2012-07-05 Avon Products, Inc. Modulation of dynein in skin

Also Published As

Publication number Publication date
CA3010395A1 (en) 2012-07-05
PL2658537T3 (pl) 2015-08-31
MX367271B (es) 2019-08-12
CN104622704B (zh) 2017-12-22
CA3010395C (en) 2020-12-15
CN104622704A (zh) 2015-05-20
HK1187251A1 (zh) 2014-04-04
HK1206591A1 (en) 2016-01-15
TW201231078A (en) 2012-08-01
BR112013014597A2 (pt) 2016-09-20
EP2987534A1 (en) 2016-02-24
EP2658537A1 (en) 2013-11-06
JP5918783B2 (ja) 2016-05-18
EP2658537B1 (en) 2015-04-29
MX2013006059A (es) 2013-07-03
WO2012091824A1 (en) 2012-07-05
EP2658537A4 (en) 2014-06-25
US8865740B2 (en) 2014-10-21
CA2817395A1 (en) 2012-07-05
CA2817395C (en) 2019-03-05
US20120165373A1 (en) 2012-06-28
BR112013014597B1 (pt) 2020-06-30
US20130253053A1 (en) 2013-09-26
CN103249409A (zh) 2013-08-14
CN103249409B (zh) 2016-07-06
TWI605833B (zh) 2017-11-21
JP2014509307A (ja) 2014-04-17
MX345299B (es) 2017-01-24
US8455518B2 (en) 2013-06-04

Similar Documents

Publication Publication Date Title
AR084598A1 (es) METODO PARA TRATAR LA PIEL CON MODULADORES DE microARN
NO20074584L (no) Peptidomimetiske forbindelser og fremstilling av biologisk aktive derivater
NO20070081L (no) Sulfamat og sulfamidderivater for behandling av epilepsi og relaterte sykdommer
NO341631B1 (no) Hydroksybenzamidderivater og deres anvendelse, fremgangsmåte for fremstilling og farmasøytiske sammensetninger
CR7718A (es) Nuevos derivados de glicosido de tiofeno, metodos para la preparacion de los mismos, medicamentos que comprenden dichos compuestos, y su uso
CY1112653T1 (el) Κρυσταλλικες τροποποιησεις της πυρακλοστροβινης
ECSP078003A (es) Inhibidores de aspartil proteasas
AR076753A1 (es) Derivados de carboxamida y urea aromaticas sustituidas como ligandos del receptor de vanilloides.
UY29781A1 (es) Compuestos diazaspiro sustituidos, sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen los compuestos o sales, métodos de preparación y usos
CR8756A (es) Derivados de acido carboxilico bencimidazolona
NO20071095L (no) Hittil ukjente tiofenderivater
NI200700056A (es) Nuevos derivados de sulfamidas de heteroaril benzo-fundido útiles como agentes anticonvulsivos
AR043648A1 (es) Derivados de bencenosulfonamida
NO20083582L (no) Pyridin-2-karboksamide derivater
NO20080408L (no) Azaindazolforbindelser og anvendelse derav
NO20082793L (no) Nye tiofenderivater
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
UY28990A1 (es) Nuevos derivados de benceno 1, 3-amino carbonilo como inhibidores de b-raf, composiciones farmacéuticas que los contienen, procesos de preparación y uso.
CO6150153A2 (es) Farmaco de compuesto de cinamida
NO20065544L (no) Urea-antagonister av P2Y1-reseptor anvendbare i behandling av trombotiske tilstander.
PA8456901A1 (es) 2-aminopiridinas que contienen sustituyentes de anillos condensados
EA201101326A1 (ru) Ингибиторы антиапоптотических белков на основе нафталина
CR9078A (es) Derivado de bencimidazol ariloxi-sustituidos
AR054347A1 (es) Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
ECSP099062A (es) Derivados novedosos de aminopiridina que tienen acción inhibidora selectiva sobre aurora a

Legal Events

Date Code Title Description
FB Suspension of granting procedure